Fatigue Affects 8 in 10 Children With IBD—Even in Remission, Study Finds

• Fatigue was reported in 81% of pediatric IBD patients, including over three-quarters in clinical remission.
• Female sex, older age, and active disease were key predictors of severe fatigue, while male sex and earlier puberty were protective.
• Fatigue was strongly associated with reduced quality of life across physical, emotional, and social domains.

Fatigue is emerging as one of the most pervasive—and underrecognized—symptoms in pediatric inflammatory bowel disease (IBD), according to a large multicenter study published in Crohn’s & Colitis 360. Drawing on data from 370 children and adolescents across 37 hospitals in Spain, the study provides one of the most comprehensive assessments to date of fatigue in this population, highlighting both its prevalence and its broad clinical implications.

The findings are striking in their consistency. More than 80% of patients aged 10 to 17 reported some degree of fatigue, and notably, this burden persisted even among those whose disease was clinically inactive. As shown in the cohort data summarized on page 4, 77.5% of patients in remission still experienced fatigue, underscoring that symptom burden extends well beyond inflammatory activity.

This disconnect between disease control and patient experience challenges traditional assumptions in IBD care. While clinicians often rely on biomarkers and clinical indices to assess remission, the study suggests that fatigue reflects a more complex interplay of biological, psychological, and social factors. Indeed, fatigue correlated strongly with diminished health-related quality of life across all domains measured by the IMPACT-III questionnaire, including emotional functioning, social participation, and general well-being.

Visual data presented on page 8 further reinforce this relationship. Patients without fatigue consistently scored higher across all quality-of-life domains, while those with severe fatigue experienced marked impairments regardless of whether they had Crohn’s disease or ulcerative colitis. The impact was particularly pronounced in social and systemic domains for Crohn’s disease and in emotional and physical domains for ulcerative colitis.

The study also sheds light on who is most at risk. Multivariate analyses identified female sex, increasing age, and active disease as independent predictors of severe fatigue. Dietary therapy was also associated with higher fatigue levels, even after adjusting for disease severity and treatment history. Conversely, the absence of fatigue was linked to male sex, earlier pubertal stage, and not receiving biologic therapy—likely reflecting both biological and disease-severity differences.

Interestingly, the study revealed discrepancies between patient and caregiver perceptions. As illustrated in the correlation matrix on page 5, while overall agreement was high, parents tended to underestimate children’s energy levels compared with self-reports. This gap highlights the subjective nature of fatigue and the importance of incorporating patient-reported outcomes into routine care.

Methodologically, the study leveraged the IMPACT-III and parent-reported IMPACT-III-P questionnaires, widely used tools for assessing quality of life in pediatric IBD. Although not specifically designed to measure fatigue, key items related to energy and tiredness provided a practical framework for large-scale evaluation. The authors note, however, that the lack of a validated, disease-specific fatigue instrument remains a significant limitation in the field.

Beyond clinical predictors, the findings point toward modifiable contributors. Prior evidence cited in the study links fatigue to poor sleep, psychosocial distress, and inflammatory mediators, suggesting opportunities for intervention beyond pharmacologic disease control. Small studies have already shown that targeted sleep hygiene interventions can improve fatigue outcomes in this population.

Taken together, the study reframes fatigue as a central component of pediatric IBD rather than a secondary symptom. Its persistence during remission and its broad impact on daily functioning argue for routine, systematic assessment in clinical practice. As the authors conclude, addressing fatigue will require a more holistic approach—one that integrates disease management with attention to psychological health, sleep, and overall well-being.

In the evolving landscape of pediatric IBD care, these findings serve as a reminder that controlling inflammation is only part of the equation. For many patients, the real burden lies in the fatigue that lingers long after the disease appears quiet.